In this episode — Investigative journalist Robert Whitaker returns for his fourth conversation with Richard. They trace the antidepressant story from the 1980 DSM-III rebrand through the reanalysis of the largest antidepressant trial ever run, the long-term data on children and stimulants, and — at the end — what Whitaker learned from the people who actually recovered.

Guest: Robert Whitaker — investigative journalist, founder of Mad in America, author of Anatomy of an Epidemic (2010), Mad in America (2002), and Psychiatry Under the Influence. His 1998 Boston Globe series was a Pulitzer finalist.

Chapters

* [00:00] The epidemic of isolation

* [02:20] Introducing Robert Whitaker

* [03:30] The 1980 DSM-III pivot

* [05:50] Where the chemical-imbalance idea came from

* [12:40] What the public was told instead

* [18:30] How the drugs change the brain

* [23:10] Patients who’ve been on SSRIs for years

* [27:53] STAR*D: the trial reanalyzed

* [37:01] Why the press stayed quiet

* [39:53] Children on psychiatric drugs

* [42:56] The MTA stimulant study

* [51:00] “A menace to society”

* [55:34] Why informed consent drives him

* [57:32] The connection cure

Introductory notes - the epidemic of isolation [00:00]

The mission of the program: enhancing wellbeing by making connections with the people who live near you, by face and by name. Ninety-five percent of people want to collaborate, not fight. A small group of dominated predators benefits from divisiveness. The current American epidemic is isolation, alienation, and loneliness. The antidote is connection - a theme the conversation returns to in its final movement.

Introducing Robert Whitaker [02:20]

Whitaker is an investigative journalist and the founder of Mad in America. He is the author of Anatomy of an Epidemic (2010), Mad in America (2002), and Psychiatry Under the Influence. His 1998 Boston Globe series on psychiatric research was a Pulitzer finalist. Of all the people I have interviewed in over twenty years, his work has had the greatest impact on my professional life.

The corruption of psychiatry and the DSM-III pivot [03:30]

* The forty-five-year story begins in 1980, when the American Psychiatric Association published DSM-III and adopted a disease model. Schizophrenia, bipolar, anxiety, and a new diagnosis called attention deficit hyperactivity disorder were each declared distinct illnesses.

* The profession said it knew the causes. Depression was too little serotonin. Psychosis was too much dopamine. A second generation of drugs would correct those imbalances, “like insulin for diabetes.”

* Prozac arrived in 1988 as a breakthrough that could make you feel “better than well.”

* Before DSM-III, American psychiatry felt its legitimacy as a medical specialty was under attack. DSM-III was a rebrand to position psychiatrists as medical doctors treating medical illnesses.

“It was pitched to us as a story of science, but it wasn’t a science story. It was a marketing story. It was a rebranding story for American psychiatry, which in the 1970s was feeling that its legitimacy as a real medical specialty was under attack.” — Robert Whitaker

What the science actually showed [05:50]

* The chemical-imbalance hypothesis came out of the 1960s, working backwards from drug mechanism, not from measurement of patient biochemistry.

* Tricyclics and MAOIs both upped serotonergic activity. Researchers inferred that depression might be low serotonin. Antipsychotics block dopamine receptors, so they inferred schizophrenia might be high dopamine.

* Direct testing failed. By 1978 researchers weren’t finding it. A 1984 NIMH study concluded that a lesion in the serotonergic system is not a cause of depression.

* In 1998, the APA’s own textbook declared the monoamine theory of depression dead. The profession did not tell the public (Moncrieff et al., 2022, Molecular Psychiatry).

What the public was told instead [12:40]

* Pharmaceutical ads kept selling SSRIs that “fix chemical imbalances.” The APA website told the same story. In 2005 the APA put out a press release calling psychiatrists experts in fixing chemical imbalances in the brain.

* Drug companies funded APA education programs, media training, and “key opinion leaders” at Stanford, Harvard, Johns Hopkins, Penn. Thought leaders were paid hundreds of thousands, sometimes more than a million, over a few years.

* By 1998, when the New England Journal of Medicine wanted a review of antidepressants, it could not find an academic mood-disorders expert who wasn’t already on pharma payroll.

My Other Books:

* Master Your Mind: Practical Tools to Calm Anxiety, Silence Your Inner Critic and Stop Overthinking

* Psychedelic Medicine at the End of Life: Dying Without Fear

* Freeing Sexuality: Psychologists, Consent Teachers, Polyamory Experts, and Sex Workers Speak Out

* Psychedelic Wisdom: The Astonishing Rewards of Mind-Altering Substances

* Psychedelic Medicine: The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca

* Integral Psychedelic Therapy (co-edited with Jason A. Butler & Genesee Herzberg)

How the drugs actually change the brain [18:30]

* Before treatment, a patient’s serotonergic system is not operating abnormally. The drug ups activity. The brain dials itself down to compensate (Hyman & Nestler, 1996, AJP).

* After long-term treatment, patients do in fact end up with a low-serotonin system, physiologically.

“The drug induces the very change that was hypothesized to cause the problem in the first place.” — Robert Whitaker

* On withdrawal, the dialed-down system can’t snap back. Patients feel terrible and conclude they are still sick.

* A University of Bristol cohort (n=222,121, 10-year follow-up, 2022) found elevated risk of coronary heart disease, cardiovascular events, and all-cause mortality among long-term antidepressant users.

What to tell patients already on SSRIs [23:10]

I described to Whitaker a patient of mine who has been on an SSRI for twenty years and no longer knows what she is without it. His answer:

* Before antidepressants became long-term care, 85% of hospitalized depressed patients recovered within a year.

* As long-term medication became standard, the one-year recovery rate dropped. By 1998, the reported stay-well figure on antidepressants was about 15%.

* A 2025 systematic review found the median antidepressant trial lasts 8 weeks. The median real-world prescription is 5 years. The science backing five-year prescribing was never built.

STAR*D - a $35 million study that became a hoax [27:53]

* STAR*D enrolled 4,041 outpatients, the largest and longest antidepressant trial ever conducted. Four chances to remit across four steps.

* Reported a 70% cumulative remission rate. Medical school curricula, the New Yorker, and the New York Times cited it.

* The protocol specified HAM-D as the outcome s...